Mayo Clinic tests vaccine to provide immune response against early breast lesion

February 1, 2017

Only about 35 percent of precancerous breast lesions morph into cancer if untreated, but physicians cannot identify which lesions are potentially dangerous. So all women diagnosed with ductal carcinoma in situ undergo traditional therapy of surgery and possibly hormonal therapy and radiation. Now, Mayo Clinic researchers are about to test a vaccine that they hope will replace standard therapies and prevent recurrence for some, if not all, these patients.

Keith Knutson, Ph.D., director of the Discovery and Translation Labs Cancer Research Program at Mayo Clinic's campus in Florida, has received a $3.7 million grant from the U.S. Department of Defense to conduct a phase II clinical trial that will test a designed to establish lifelong immunity against development of these precancerous lesions.

If ultimately successful, the vaccine could substitute for current in situ therapy and may become part of a routine immunization schedule in healthy women.

"We ultimately want to eliminate ductal carcinoma in situ, which means preventing disfiguring surgeries and toxic therapies in the 60,000 women who receive this diagnosis every year in the U.S.," says Dr. Knutson, who designed the vaccine.

Eliminating ductal carcinoma in situ also would reduce the overall breast cancer burden significantly, he adds. "Ductal carcinoma in situ is a significant health problem, accounting for about 20 percent of U.S. cases of breast cancer."

Beginning in 2017, Dr. Knutson and his colleagues at the Mayo Clinic campuses in Florida and Rochester, Minnesota, will test the vaccine in 40-45 patients diagnosed with ductal carcinoma in situ. These patients will be treated with the vaccine first. Six weeks later, they will receive surgery (lumpectomy or mastectomy) and other standard therapy. During the initial six weeks, physicians will monitor patients to see if ductal carcinoma in situ lesions reacted to the vaccine.

"The hope is that they disappear," says Dr. Knutson. If successful, advanced clinical trials could be designed to test the possibility that vaccination may be a "safe alternative to conventional and problematic" treatment for ductal carcinoma in situ, he says.

The new grant is the second that Dr. Knutson and his team have received from the U.S. Department of Defense to test a breast cancer vaccine. In 2015, they received a five-year $13.3 million U.S. Department of Defense Breakthrough Award to fund a phase II clinical trial testing a different breast cancer vaccine that Dr. Knutson had developed. That vaccine is designed to prevent the recurrence of , which is a subset of breast cancer for which there are no targeted therapies. A phase I trial of the vaccine found it to be safe.

The vaccine to be tested on ductal carcinoma in situ also has been tested in a phase I clinical study. This vaccine is targeted against human epidermal growth factor 2 (HER-2), an oncogene known to play a role in the development and progression of an aggressive subtype of breast cancer known as HER-2 positive.

Dr. Knutson suspects that excess HER-2 proteins are expressed in all subtypes of breast cancer, including the most common one: estrogen-positive breast cancer. He says that the phase I study of the HER-2 vaccine elicited an immune response in all tested individuals. The vaccine is designed to stimulate production of T cells that target initial development of ductal carcinoma in situ.

"We don't know if the vaccine works just on HER-2 ," he says. "We believe that once an immune response is generated against the ductal in situ lesion, it doesn't matter what subtype of cancer the lesion may become."

Explore further: Vaccine shows promising results for early-stage breast cancer patients

Related Stories

Vaccine shows promising results for early-stage breast cancer patients

January 3, 2017
Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system to recognize cancer cells and target them for destruction. Researchers ...

Reoperation risk for nonpalpable breast lesions higher for DCIS

December 29, 2016
(HealthDay)—For women undergoing wire-guided breast conserving surgery (BCS) for nonpalpable breast lesions, the risk of reoperation is higher for those with ductal carcinoma in situ (DCIS) than those with invasive breast ...

Common breast cancer test may not be worth the cost, study suggests

September 14, 2016
A new study by a UCLA researcher in collaboration with colleagues at Harvard and University of Texas Southwestern has found that a genomic test widely used to help determine whether women with a common form of breast cancer ...

Women treated for precursor of breast cancer can expect to live as long as other women

January 27, 2017
Women over 50 who have been treated for ductal carcinoma in situ (DCIS) are more likely to be alive ten years later than women in the general population, according to new research presented at the European Cancer Congress ...

Mayo Clinic receives FDA approval for ovarian and breast cancer vaccines

August 17, 2011
Mayo Clinic has received investigational new drug approval from the Food and Drug Administration for two new cancer vaccines that mobilize the body's defense mechanisms to destroy malignant cells. The vaccines are among the ...

SABCS: Genetic test may help predict DCIS recurrence

December 14, 2014
(HealthDay)—For women who have ductal carcinoma in situ surgically removed, a genetic test may help predict the odds of a recurrence, according to research presented at the annual San Antonio Breast Cancer Symposium, held ...

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.